Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

Group 1 - Fulgent Genetics, Inc. announced preliminary clinical data from its ongoing phase 2 clinical trial for FID-007 in combination with cetuximab [1] - The trial focuses on the second-line treatment of patients with recurrent or metastatic head and neck cancer [1]